Thioredoxin as a Novel Serological Biomarker in Alpha-Fetoprotein Negative  Hepatocellular Carcinoma: Evidence and Mechanisms

Amany Mohamed Ibrahim  , Khaled Mounir Attia  ,Mahmoud Amer , Abdullah Mohamad Abd el hameed

Thioredoxin as a Novel Serological Biomarker in Alpha-Fetoprotein Negative Hepatocellular Carcinoma: Evidence and Mechanisms

Authors

Amany Mohamed Ibrahim , Khaled Mounir Attia ,Mahmoud Amer , Abdullah Mohamad Abd el hameed

Keywords:

Thioredoxin, Alpha-Fetoprotein, Negative Hepatocellular Carcinoma

Abstract

Background: Hepatocellular carcinoma (HCC) represents a global health challenge with high mortality, largelydriven by late diagnosis. Alpha- etoprotein (AFP), the conventional serological benchmark for HCC surveillance anddiagnosis, exhibits suboptimal sensitivity and specificity, with a significant proportion of patients, up to 40%,presenting with AFP-negative HCC.

References

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.

Downloads

Published

2024-05-20

How to Cite

Amany Mohamed Ibrahim , Khaled Mounir Attia ,Mahmoud Amer , Abdullah Mohamad Abd el hameed. (2024). Thioredoxin as a Novel Serological Biomarker in Alpha-Fetoprotein Negative Hepatocellular Carcinoma: Evidence and Mechanisms . Journal of Computational Analysis and Applications (JoCAAA), 33(06), 3084–3101. Retrieved from https://eudoxuspress.com/index.php/pub/article/view/3964